INDIA – India’s fastest growing diagnostics service provider Redcliffe Labs has launched its BD MAX Multi-Drug Resistant Tuberculosis (MDR-TB) Assay, performed on the BD MAX System, into the Indian market.
Redcliffe’s BD MAX MDR TB test is an automated qualitative in vitro diagnostic test that will allow clinicians to rapidly test for TB and multidrug resistance as a first-line test and ultimately improve patient outcomes.
Traditionally, clinicians perform two different tests to detect multidrug-resistant tuberculosis – one to detect TB and one to check for drug resistance – against only one drug (Rifampicin).
With the new diagnostic test developed by Redcliffe Labs, drug resistance against both Rifampicin and Isoniazid can be detected in a single test for high diagnostic accuracy for TB testing.
“Clinicians can use the test to simultaneously detect bacteria that cause TB and determine if the bacteria contain mutations associated with resistance to two important first-line drugs, namely Isoniazid (INH) and Rifampicin (RIF) respectively,” the company claimed.
BD MAX MDR-TB is a real-time PCR assay with a high level of sensitivity, detecting Mycobacterium tuberculosis complex (MTBC) as well as key mutations associated with RIF and INH resistance.
In addition to diagnostic prowess, the new rapid molecular test for MDR-TB in India will support the country to achieve its ambitious goal of eliminating tuberculosis by 2025.
The latest product launch aligns with Redcliffe’s focus on improving the diagnosis of TB by providing clinicians with the best tools for identifying effective treatments for their patients.
The development comes barely a month after the diagnostic provider expanded its operations in Punjab’s three major cities, namely Bhatinda, Ludhiana, and Jalandhar.
Redcliffe Labs carries out its home sample collection service in more than 120 cities with 30+ Labs and 700+ Walk-in Wellness and Collection Centres across India.
It aims to make health tests accessible to all Indians through a perfect fusion of technology and world-class state-of-the-art owned labs and a trusted radiology network.
“With the launch of each lab across Bharat, we are growing closer to our objective of providing quality diagnostics to Indians and clinicians helping them to make the right informed clinical decision,” Dheeraj Jain, Founder and Managing Director (MD), Redcliffe Labs said in a statement.
The company is merely following a growing trend of pharma giants opting to launch highly accurate and effective diagnostic tests for infectious diseases in India.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
Be the first to leave a comment